The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients With Post-acute COVID-19 Syndrome.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-17

Study Completion Date

2022-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Food supplements like curcumin and boswellia serrata have been used traditionally for anti-inflammatory purposes. A well-known problem of these substances in their natural form is the low bioavailability. Micellization of these substances has been shown to increase the bioavailability significantly and thereby the clinical efficacy. The clinical value of these micellized substances has been presented in numerous clinical studies and in particular in patients with acute COVID-19. This study aims to examine the effect of a mixture of micellized curcumin, boswellia serrata and ascorbic acid on patients with long COVID.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of 8 Weeks of Turmeric Ingestion on Physiology and Wellbeing in Healthy Older Adults

NCT07196514

Turmeric Placebo

RECRUITING NA

Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19

NCT05130671

COVID-19

COMPLETED NA

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

NCT02998918

Inflammation Atherosclerosis Cardiovascular Disease

COMPLETED NA

Effects of Botanical Microglia Modulators in Gulf War Illness

NCT02909686

Gulf War Illness

COMPLETED NA

Oral Curcumin, Quercetin and Vitamin D3 Supplements for Mild to Moderate Symptoms of COVID-19

NCT04603690

Covid-19

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants will be asked to take the micellized supplements daily, at home for 6 weeks. During this 6 weeks several questionnaires will be taken to asses general health-related quality of life. Follow-up measurements will be done at 14 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-acute COVID-19 Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single-arm intervention

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Curcumin/Boswellia Serrata/Ascorbic acid mixture

The daily intake of 2x10 drops of a mixture of micellized curcumin(2%), boswellia serrata (1,5%) and ascorbic acid (6%).

Group Type EXPERIMENTAL

Curcumin/Boswellia Serrata/Ascorbic acid mixture

Intervention Type DIETARY_SUPPLEMENT

The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Curcumin/Boswellia Serrata/Ascorbic acid mixture

The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with confirmed SARS-CoV-2 infection at least 28 days prior to study participation
* Patients who are experiencing symptoms of PACS (with a PCFS of 1 or higher)
* 18 years or older and younger than 85
* Good understanding of written German

Exclusion Criteria

* Currently under pharmacological treatment for PACS
* Any planned medical surgery or intervention where medication intake is necessary in the coming 14 weeks
* Allergy to curcumin or Boswellia
* Active malignancy
* Medical history of Human Immunodeficiency Virus (HIV) infection, or any serious immunocompromised state.
* Pregnancy (or planned pregnancy in the coming 14 weeks) ( - Patients who are taking anticoagulants or have diabetes type I or II are only allowed to participate if their general practitioner is informed)

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No